MENLO PARK, Calif., April 28, 2026 (GLOBE NEWSWIRE) — Oruka Therapeutics, Inc. (Nasdaq: ORKA), a clinical-stage biopharmaceutical company focapplyd on…
Read More

MENLO PARK, Calif., April 28, 2026 (GLOBE NEWSWIRE) — Oruka Therapeutics, Inc. (Nasdaq: ORKA), a clinical-stage biopharmaceutical company focapplyd on…
Read More
Oruka Therapeutics has recently filed two major shelf registrations exceeding US$1.25 billion and announced a US$200 million follow-on equity offering…
Read More